Company*
(Country; Symbol)

Company*
(Country; Symbol)

Type/Product Area

Terms/Details (Date)

November

3SBio Inc. (China; SSRX)

EnzymeRx LLC*

Worldwide rights agreement for pegsiticase for all indications

3SBio is paying $6.25M for the rights, and intends to develop it in China (11/30)

Alnylam Pharmaceuticals Inc. (ALNY)

Tekmira Pharmaceuticals Corp. (Canada; TSX:TKM)

Licensing agreement for InterfeRx to discover, develop and commercialize an RNAi therapeutic for treating Ebola virus infection

The deal includes royalties on sales of any resulting product (11/5)

Apeiron Biologics AG* (Austria)

Polymun Scientific GmbH* (Austria)

Exclusive rights agreement to recombinant super oxide dismutase from Polymun

The deal is for clinical development of a topical formulation to treat certain inflammatory skin conditions such as skin damage related to cancer radiation therapy (11/5)

BioSante Pharmaceuticals Inc. (BPAX)

Cold Genesys Inc.*

Exclusive, worldwide rights deal to develop and commercialize its oncolytic virus technology

BioSante gains a 19.9% ownership in Cold Genesys and a $95,000 up-front cash payment; it also is eligible for undisclosed future milestone and royalty payments (11/18)

BioWa Inc. (subsidiary of Kyowa Hakko Kirin Co. Ltd.; Japan)

Agensys Inc. (affiliate of Astellas Pharma Inc.; Japan)

Licensing agreement for BioWa's Potelligent technology for antibody discovery

Terms were not disclosed (11/16)

Compugen Ltd. (Israel; CGEN)

Seattle Genetics Inc. (SGEN)

Research collaboration covering a Compugen-discovered oncology target

Seattle Genetics gets an option for an exclusive worldwide milestone and royalty-bearing license for development and commercialization of monoclonal antibody therapeutics addressing the target (11/1)

DiscoveRx Corp.*

Ambit Biosciences*

Deal for DiscoveRx to acquire the KINOMEscan kinase screening services division from Ambit

The company said it would further strengthen its position in validated GPCR and kinase assays for high-throughput screening and profiling (11/19)

Eden Biodesign Ltd. (UK; unit of Watson Pharmaceuticals Inc.)

Crucell NV (the Netherlands; CRXL)

Nonexclusive vendor network agreement under which Eden will offer its services to Crucell's PER.C6 licensees in the field of vaccines and gene therapy

No financial terms were disclosed (11/11)

Fabrus LLC*

Ambrx Inc.*

Research program to discover antibodies with properties that are optimized for use as antibody drug conjugates

Ambrx gains exclusive rights to commercialize conjugated forms of the antibodies; Fabrus will receive up-front payments and is eligible for milestone payments and a share of certain payments received by Ambrx in the future (11/10)

Horizon Discovery Ltd.*

Mirna Therapeutics Inc.*

Collaboration to test the impact of Mirna's miRNA mimics on a panel of Horizon's patient-relevant human isogenic cancer cell models

Horizon's X-MAN human cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics (11/3)

IntelGenx Corp. (Canada; CDNX:IGX)

PediPharm Ltd.*; Cynapsus Therapeutics Inc. (Canada; CDNX:CTH)

Deal acquiring exclusive, worldwide rights to INT0010 for neuropathic pain in multiple sclerosis and chemotherapy-induced nausea from PediPharm

PediPharm will get an up-front fee and milestone payments, plus royalties; IntelGenx also made an agreement with Cynapsus to receive full control and interest in the drug in exchange for debt forgiveness and royalty payments (11/30)

Isis Pharmaceuticals Inc. (ISIS)

Xenon Pharmaceuticals Inc.* (Canada)

Deal to discover and develop antisense drugs to treat the common disease anemia of inflammation

Isis will get an undisclosed up-front payment in the form of a convertible promissory note from Xenon to discover and develop antisense drugs to the targets hemojuvelin and hepcidin (11/17)

Isotechnika Pharma Inc. (Canada; TSX:ISA)

Iljin Life Science Co. Ltd.* (unit of the Iljin Group; South Korea)

Development, distribution and license deal for the further clinical and commercial development of voclosporin for use in transplant indications

Iljin agreed to fund a single Phase III trial in kidney transplantation through a combination of a $5M license fee and the purchase, in three tranches, of common stock; Iljin gains rights for transplant and autoimmune indications for the U.S. and other regions outside of Canada, Israel, South Africa, Europe, China, Taiwan and Hong Kong; Isotechnika retains rights over voclosporin in Europe (11/17)

London Genetics Ltd.* (UK)

Astrimmune Ltd.* (UK)

Deal to plan a biomarker identification program for Astrimmune's early stage pancreatic cancer vaccine candidate

Financial terms were not disclosed (11/15)

Maxygen Inc. (MAXY)

Codexis Inc. (CDXS)

Deal to sell Maxygen's MolecularBreeding platform technology to Codexis

Codexis is paying $20M in cash; the sale includes the cancellation of all payment and potential royalty obligations of Codexis relating to biofuels and other energy products (11/1)

Merrion Pharmaceuticals plc (Ireland; PK:MNHPF)

Rebel Pharmaceuticals LLC*

Agreement to evaluate Merrion's Gipet technology to improve Rebel's products

Upon completion of the feasibility study, the companies will execute a license agreement (11/24)

Omeros Corp. (OMER)

Patobios Ltd.* (Canada)

Completed acquisition of a GPCR assay technology comprising patents and other intellectual property rights from Patobios

The purchase price was C$10.8 ($10.5M), of which C$7.8M was paid in cash and the remaining was paid in 379,039 shares of Omeros common stock (11/24)

SurModics Inc. (SRDX)

Edge Therapeutics Inc.*

Collaboration for a feasibility study of SurModics' NimoGel for delayed cerebral ischemia

Edge will provide funding for development and commercialization and SurModics will provide technology and manufacturing expertise; SurModics will receive licensing fees, milestone payments and royalties (11/5)

December

Adimab Inc.*

Genentech Inc. (NYSE:DNA), Human Genome Sciences Inc. (HGSI) and Eli Lilly and Co.

Adimab initiated three new research collaborations for the use of its antibody discovery platform technology

Financial terms were not disclosed (12/16)

AltheaDx Inc.*

Compendia Bioscience Inc.*

Partnership to jointly discover novel products and services in the area of cancer biomarkers

Terms were not disclosed (12/9)

Apricus Biosciences Inc. (APRI)

Bracco SpA* (Italy)

Licensing agreement granting Bracco exclusive rights to market Vitaros, a topical treatment for erectile dysfunction

Apricus will get up to $7.2M in up-front, regulatory and sales milestones, plus tiered, double-digit royalties based on Bracco's sales of the product (12/23)

Biogen Idec Inc. (BIIB)

Neurimmune Holding AG* (Switzerland)

Biogen Idec acquired three preclinical immunotherapy programs focused on Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis

Biogen will pay $32.5M up front and as much as $395M in contingent payments to Neurimmune for a subsidiary that includes the worldwide rights to the programs (12/22)

Cellectis SA (France; Paris:ALCLS)

Harvard Apparatus (a division of Harvard Bioscience Inc.; HBIO)

License agreement that gives Harvard the worldwide exclusive rights to manufacture and sell, for research use, the full line of electroporation-based instruments, which Cellectis gained in its acquisitions of CytoPulse Sciences Inc.

Cellectis will receive a payment of $1.3M and retains all rights to the use of the products for its own research and development programs (12/3)

Cephalon Inc. (CEPH)

Mesoblast Ltd. (Australia; ASX:MSB)

Deal for exclusive worldwide rights to products based on Mesoblast's stem cell technology

Cephalon will pay $130M for the rights, plus milestones that could boost the deal's value to $1.7B; Cephalon also will buy 19.99% of Mesoblast's outstanding shares for a total of about $220M (12/9)

iCo Therapeutics Inc. (Canada; CDNX:ICO)

Immune Pharmaceuticals* (Israel)

Deal for an exclusive license for the development and commercialization rights to the systemic uses of iCo-008 in inflammatory bowel disease and severe asthma

iCo will retain worldwide exclusive rights to all ocular applications; IMPH will pay iCo an option fee creditable upon conversion against an up-front license fee payment of $1M; iCo may receive $32M in milestone payments, in addition to royalties on net sales (12/10)

Immunovaccine Inc. (Canada; CDNX:IMV)

OncoTherapy Science Inc.* (Japan)

Collaborative research agreement to explore the efficacy of their peptide cancer antigen in Immuno-vaccine's DepoVax vaccine delivery and enhancement platform

Financial terms were not disclosed (12/1)

Metamark Genetics Inc.*

HistoRx Inc.*

Multiyear licensing agreement with HistoRx granting Metamark worldwide rights to the AQUA technology for clinical commercialization of Metamark's prognostic assays

Financial terms were not disclosed (12/21)

miRagen Therapeutics Inc.*

t2cure GmbH* (Germany)

Licensing agreement that provides miRagen with exclusive rights to the technology and intellectual property related to the in vivo use of discoveries made by the University of Frankfurt and licensed by t2cure regarding microRNA 92

miR-92 is a key regulator of neoangiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders (12/1)

MonoSol Rx*

Midatech Group Ltd.* (UK)

Agreement to form a joint venture to develop products for diabetes

Financial terms were not disclosed (12/9)

Oxygen Biotherapeutics Inc. (OXBT)

Sarasota Medical Products Inc.*

Binding letter of intent to determine the feasibility of pursuing a joint venture in chronic ischemic wounds based on the combination of Oxygen's Wundecyte PFC formulation with SMP's topical medical devices

Wundecyte is designed to deliver oxygen to a wound alone or in combination with a specialized oxygenating bandage (12/17)

Paladin Labs Inc. (Canada; TSX:PLB)

ProStrakan Group plc (UK; LSE:PSK)

Agreement in which Paladin will get an exclusive license to ProStrakan's products for certain emerging territories and will acquire, by way of assignment, ProStrakan's existing secured debt facility with the addition of certain conversion rights

The $78M secured facility will be amended, with capital repayment not due until early January 2014 (12/17)

PolyTherics Ltd.* (UK)

MacroGenics Inc.*

Collaboration to apply PolyTherics' site-specific pegylation technologies to an initial dual-affinity re-targeting protein for evaluation by MacroGenics

MacroGenics has the option to use PolyTherics' technologies for additional DART candidates in the future and holds an option to license use of the technologies for further development and commercialization activities (12/7)

Recordati SpA (Italy; Milan:REC)

Nymox Pharmaceutical Corp. (NYMX)

European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III drug in development to treat benign prostatic hyperlasia

Recordati will receive exclusive rights to develop and market NX-1207 in Europe, including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (12/20)

Notes:

* Private companies are indicated with an asterisk. Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets; TSX = Toronto Stock Exchange.